Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Cocaine-Related Disorders · Cocaine Dependence · DRUG

BRIGHT MINDS BIOSCIENCES

BRIGHT MINDS BIOSCIENCES INC.

BRIGHT MINDS BIOSCIENCES clinical programs — 1063 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
19 Vestry St, New York, NY 10013, US HQ
12 Employees
Public company Type
DRUG · NYSE Ticker
Company details
Status
Public
HQ
19 Vestry St, New York, NY 10013, US
Employees
12
Programs
1063
Drugs
444
Patents
57
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

BRIGHT MINDS BIOSCIENCES projects

1,063 ClinicalTrials.gov programs sponsored by BRIGHT MINDS BIOSCIENCES.

BRIGHT MINDS BIOSCIENCES has 1,063 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

1,063 programs

Clinical programs

Page 10 of 23

  1. Selegiline

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    3 trials

  2. Selegiline

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 small molecule completed

    1 trial

  3. Selegiline Transdermal Patch

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 small molecule completed

    1 trial

  4. Selegiline hydrochloride

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Abuse

    phase 2 small molecule completed

    1 trial

  5. Semaglutide

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorder

    phase 2 small molecule active

    1 trial

  6. Semaglutide Pen Injector

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 2 small molecule active

    1 trial

  7. Senicapoc

    BRIGHT MINDS BIOSCIENCES INC.

    Mild Cognitive Impairment

    phase 2 small molecule active

    1 trial

  8. Sertraline

    BRIGHT MINDS BIOSCIENCES INC.

    Alcoholism

    phase 2 small molecule terminated

    1 trial

  9. Sertraline

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  10. Sildenafil 50 mg Oral Tablet

    BRIGHT MINDS BIOSCIENCES INC.

    Erectile Dysfunction

    phase 2 small molecule completed

    1 trial

  11. Smoking research cigarettes with e-cigarette

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Addiction

    phase 2 small molecule completed

    1 trial

  12. Sofosbuvir

    BRIGHT MINDS BIOSCIENCES INC.

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  13. Standard Cognitive Behavioral Treatment

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 2 other completed

    1 trial

  14. Standard Treatment As Usual (TAU)

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 2 other completed

    1 trial

  15. Standard drug counseling

    BRIGHT MINDS BIOSCIENCES INC.

    Opiate Dependence

    phase 2 other completed

    1 trial

  16. Standard intervention (counseling + self-help written materials)

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use

    phase 2 other completed

    1 trial

  17. Standard of Care with Lofexidine

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Withdrawal (Disorder)

    phase 2 small molecule active

    1 trial

  18. Standard of care and PrEP Choice at Enrollment

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 other active

    1 trial

  19. Study 3: Chronic care management

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking, Tobacco

    phase 2 other completed

    1 trial

  20. Suboxone Remote Observed Dosing

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-use Disorder

    phase 2 other completed

    1 trial

  21. Sugammadex Injection 2mg/kg

    BRIGHT MINDS BIOSCIENCES INC.

    Anesthesia, General

    phase 2 small molecule completed

    1 trial

  22. THC

    BRIGHT MINDS BIOSCIENCES INC.

    THC

    phase 2 small molecule active

    1 trial

  23. TMC207

    BRIGHT MINDS BIOSCIENCES INC.

    Pulmonary Tuberculosis

    phase 2 small molecule completed

    1 trial

  24. TMC207 (J)

    BRIGHT MINDS BIOSCIENCES INC.

    Pulmonary Tuberculosis

    phase 2 small molecule completed

    1 trial

  25. TNX-1300 (Injection)

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use

    phase 2 small molecule terminated

    1 trial

  26. TRV734

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Use Disorder

    phase 2 small molecule completed

    1 trial

  27. Target-controlled naloxone-infusion

    BRIGHT MINDS BIOSCIENCES INC.

    Central Nervous System Sensitization

    phase 2 small molecule completed

    1 trial

  28. Telacebec

    BRIGHT MINDS BIOSCIENCES INC.

    Buruli Ulcer

    phase 2 small molecule active

    1 trial

  29. Test Drug

    BRIGHT MINDS BIOSCIENCES INC.

    Heroin Dependence

    phase 2 small molecule terminated

    1 trial

  30. Theory-based counseling program

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 2 other completed

    1 trial

  31. Tiagabine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  32. Tirzepatide

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use Disorder

    phase 2 small molecule active

    1 trial

  33. Tirzepatide

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    phase 2 small molecule active

    1 trial

  34. Tobacco free snuff

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 small molecule completed

    1 trial

  35. Tolcapone

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 small molecule completed

    1 trial

  36. Topiramate

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Abuse

    phase 2 small molecule completed

    1 trial

  37. Topiramate

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  38. Tramadol

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 2 small molecule completed

    2 trials

  39. Transdermal Nicotine Patch

    BRIGHT MINDS BIOSCIENCES INC.

    Cigarette Smoking

    phase 2 small molecule completed

    1 trial

  40. Transdermal Nicotine patch

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Smoking

    phase 2 small molecule completed

    1 trial

  41. Tyrosine

    BRIGHT MINDS BIOSCIENCES INC.

    Amphetamine-Related Disorders

    phase 2 other completed

    1 trial

  42. VIVITROL (Naltrexone extended-release injectable suspension)

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    1 trial

  43. Vaccine PvCS N+C+R

    BRIGHT MINDS BIOSCIENCES INC.

    Malaria

    phase 2 mab completed

    1 trial

  44. Vaccine PvCS N+C+R 150 mcg

    BRIGHT MINDS BIOSCIENCES INC.

    Malaria, Vivax

    phase 2 mab active

    1 trial

  45. Valproate

    BRIGHT MINDS BIOSCIENCES INC.

    Bipolar Disorder

    phase 2 small molecule completed

    1 trial

  46. Varenicline

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use

    phase 2 small molecule active

    1 trial

  47. Varenicline

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol Dependence

    phase 2 small molecule completed

    1 trial

  48. Varenicline

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule terminated

    2 trials

Frequently asked questions

How many clinical projects does BRIGHT MINDS BIOSCIENCES have?

1,063 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.